ANT-006 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Alomone Labs probdnf antibody
    Probdnf Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/probdnf antibody/product/Alomone Labs
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    probdnf antibody - by Bioz Stars, 2023-02
    94/100 stars
      Buy from Supplier

    91
    Alomone Labs guinea pig anti probdnf
    Guinea Pig Anti Probdnf, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/guinea pig anti probdnf/product/Alomone Labs
    Average 91 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    guinea pig anti probdnf - by Bioz Stars, 2023-02
    91/100 stars
      Buy from Supplier

    94
    Alomone Labs anti probdnf antibody
    Mapping of <t>proBDNF-sortilin</t> interaction interface. (A) Schematic diagram illustrating the design of human BDNF prodomain variants. Six variants with a series of amino acids deletions were used in this study. V66M, Val66Met; S, Signal peptide (amino acid 1-18); BDNF, mature BDNF (amino acid 129-247); HA, C-terminal HA epitope. (B) Immunoblots of co-immunoprecipitation (Left) or inputs (Right) of sortilin and proBDNF variants obtained with antibody against HA or Myc epitope. IP, Immunoprecipitation; IB, Immunoblot. (C) Left , live fluorescence micrograph of BiFC mapping assay (Yellow) using HEK293T cells with VC155-sortilin (Sort1) and VN155(I152L)-BDNF prodomain variants. Scale bar represents 50 µm. Right , quantification of fluorescence intensity of BiFC assay. P <0.0001, one-way ANOVA. ** P <0.01 versus Fl group; *** P <0.0001 versus Fl group; ## P <0.001 versus variant I; ### P <0.0001 versus variant I group; n.s., non-significant. Values are means ± SEM. n = 100 individual cells from 4 images. (D) Left , representative immunoblots of supernatant and cell lysates of HEK293 cells overexpressing sortilin and BDNF prodomain variants obtained <t>with</t> <t>antibodies</t> against HA. Right , densitometry analyses of secreted BDNF in supernatants, normalized to input in lysates. P <0.001, one-way ANOVA. * P <0.05, versus Fl group; *** P <0.001, versus Fl group; ## P <0.05, versus I group. Values are means ± SEM. n = 4. IB, Immunoblot. (E) BDNF ELISA quantification of supernatant collected from HEK293 cells overexpressing sortilin and BDNF prodomain variants. P <0.0001, one-way ANOVA. * P <0.05; ** P <0.01; *** P <0.001, versus Sort1/Fl group; ## P <0.05, versus Sort1/variant I group. Values are means ± SEM. Each data point represents the average of 3 independent experiments.
    Anti Probdnf Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti probdnf antibody/product/Alomone Labs
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti probdnf antibody - by Bioz Stars, 2023-02
    94/100 stars
      Buy from Supplier

    86
    Alomone Labs rabbit polyclonal antibody
    α-BDNF, α-Myc, and α–pro-BDNF antibodies all generate similar staining patterns. (A) A schematic representation of the BDNF precursor pro-BDNF and the two cleavage products pro-peptide and BDNF. (B) Low-power view of a WT hippocampal section stained with anti-BDNF antibodies. Note the intense staining in the hilus of the DG and in SL of CA3, each of which contains the axon terminals of mossy fibers. (C and D) Higher magnification view of the DG (C) and CA3 region (D) of the cbdnf ko hippocampus stained with anti-BDNF. Note the absence of immunoreactive signals in all cellular and neuropil layers. GCL, granule cell layer; H, hilus; IML, inner molecular layer; PCL, pyramidal cell layer. (E) Bdnf-Myc hippocampi stained with Myc antibodies show a similar staining pattern to that produced by BDNF antibodies. (F and G) Note the absence of staining in the corresponding DG (F) and CA3 regions (G) of WT sections treated with Myc antibodies. (H) <t>Polyclonal</t> pro-BDNF antibodies yield a similar pattern to that of anti-BDNF. (I and J) The same antibodies do not produce an immunoreactive signal in hippocampal sections from cbdnf ko animals. (B, E, and H) Arrows denote the end bulb of the mossy fiber projection, which delineates CA3 and CA1. Note the relative lack of staining in CA1 in WT and Bdnf-Myc sections. Bars: (B, E, and H) 500 µm; (C, F, and I) 100 µm; (D, G, and J) 50 µm.
    Rabbit Polyclonal Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit polyclonal antibody/product/Alomone Labs
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit polyclonal antibody - by Bioz Stars, 2023-02
    86/100 stars
      Buy from Supplier

    86
    Alomone Labs growth receptors rabbit polyclonal ant 006
    α-BDNF, α-Myc, and α–pro-BDNF antibodies all generate similar staining patterns. (A) A schematic representation of the BDNF precursor pro-BDNF and the two cleavage products pro-peptide and BDNF. (B) Low-power view of a WT hippocampal section stained with anti-BDNF antibodies. Note the intense staining in the hilus of the DG and in SL of CA3, each of which contains the axon terminals of mossy fibers. (C and D) Higher magnification view of the DG (C) and CA3 region (D) of the cbdnf ko hippocampus stained with anti-BDNF. Note the absence of immunoreactive signals in all cellular and neuropil layers. GCL, granule cell layer; H, hilus; IML, inner molecular layer; PCL, pyramidal cell layer. (E) Bdnf-Myc hippocampi stained with Myc antibodies show a similar staining pattern to that produced by BDNF antibodies. (F and G) Note the absence of staining in the corresponding DG (F) and CA3 regions (G) of WT sections treated with Myc antibodies. (H) <t>Polyclonal</t> pro-BDNF antibodies yield a similar pattern to that of anti-BDNF. (I and J) The same antibodies do not produce an immunoreactive signal in hippocampal sections from cbdnf ko animals. (B, E, and H) Arrows denote the end bulb of the mossy fiber projection, which delineates CA3 and CA1. Note the relative lack of staining in CA1 in WT and Bdnf-Myc sections. Bars: (B, E, and H) 500 µm; (C, F, and I) 100 µm; (D, G, and J) 50 µm.
    Growth Receptors Rabbit Polyclonal Ant 006, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/growth receptors rabbit polyclonal ant 006/product/Alomone Labs
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    growth receptors rabbit polyclonal ant 006 - by Bioz Stars, 2023-02
    86/100 stars
      Buy from Supplier

    Image Search Results


    Mapping of proBDNF-sortilin interaction interface. (A) Schematic diagram illustrating the design of human BDNF prodomain variants. Six variants with a series of amino acids deletions were used in this study. V66M, Val66Met; S, Signal peptide (amino acid 1-18); BDNF, mature BDNF (amino acid 129-247); HA, C-terminal HA epitope. (B) Immunoblots of co-immunoprecipitation (Left) or inputs (Right) of sortilin and proBDNF variants obtained with antibody against HA or Myc epitope. IP, Immunoprecipitation; IB, Immunoblot. (C) Left , live fluorescence micrograph of BiFC mapping assay (Yellow) using HEK293T cells with VC155-sortilin (Sort1) and VN155(I152L)-BDNF prodomain variants. Scale bar represents 50 µm. Right , quantification of fluorescence intensity of BiFC assay. P <0.0001, one-way ANOVA. ** P <0.01 versus Fl group; *** P <0.0001 versus Fl group; ## P <0.001 versus variant I; ### P <0.0001 versus variant I group; n.s., non-significant. Values are means ± SEM. n = 100 individual cells from 4 images. (D) Left , representative immunoblots of supernatant and cell lysates of HEK293 cells overexpressing sortilin and BDNF prodomain variants obtained with antibodies against HA. Right , densitometry analyses of secreted BDNF in supernatants, normalized to input in lysates. P <0.001, one-way ANOVA. * P <0.05, versus Fl group; *** P <0.001, versus Fl group; ## P <0.05, versus I group. Values are means ± SEM. n = 4. IB, Immunoblot. (E) BDNF ELISA quantification of supernatant collected from HEK293 cells overexpressing sortilin and BDNF prodomain variants. P <0.0001, one-way ANOVA. * P <0.05; ** P <0.01; *** P <0.001, versus Sort1/Fl group; ## P <0.05, versus Sort1/variant I group. Values are means ± SEM. Each data point represents the average of 3 independent experiments.

    Journal: Theranostics

    Article Title: A Novel Peptide Interfering with proBDNF-Sortilin Interaction Alleviates Chronic Inflammatory Pain

    doi: 10.7150/thno.29703

    Figure Lengend Snippet: Mapping of proBDNF-sortilin interaction interface. (A) Schematic diagram illustrating the design of human BDNF prodomain variants. Six variants with a series of amino acids deletions were used in this study. V66M, Val66Met; S, Signal peptide (amino acid 1-18); BDNF, mature BDNF (amino acid 129-247); HA, C-terminal HA epitope. (B) Immunoblots of co-immunoprecipitation (Left) or inputs (Right) of sortilin and proBDNF variants obtained with antibody against HA or Myc epitope. IP, Immunoprecipitation; IB, Immunoblot. (C) Left , live fluorescence micrograph of BiFC mapping assay (Yellow) using HEK293T cells with VC155-sortilin (Sort1) and VN155(I152L)-BDNF prodomain variants. Scale bar represents 50 µm. Right , quantification of fluorescence intensity of BiFC assay. P <0.0001, one-way ANOVA. ** P <0.01 versus Fl group; *** P <0.0001 versus Fl group; ## P <0.001 versus variant I; ### P <0.0001 versus variant I group; n.s., non-significant. Values are means ± SEM. n = 100 individual cells from 4 images. (D) Left , representative immunoblots of supernatant and cell lysates of HEK293 cells overexpressing sortilin and BDNF prodomain variants obtained with antibodies against HA. Right , densitometry analyses of secreted BDNF in supernatants, normalized to input in lysates. P <0.001, one-way ANOVA. * P <0.05, versus Fl group; *** P <0.001, versus Fl group; ## P <0.05, versus I group. Values are means ± SEM. n = 4. IB, Immunoblot. (E) BDNF ELISA quantification of supernatant collected from HEK293 cells overexpressing sortilin and BDNF prodomain variants. P <0.0001, one-way ANOVA. * P <0.05; ** P <0.01; *** P <0.001, versus Sort1/Fl group; ## P <0.05, versus Sort1/variant I group. Values are means ± SEM. Each data point represents the average of 3 independent experiments.

    Article Snippet: The primary antibodies used included anti-proBDNF antibody (#ANT-006-AG, Alomone Labs Ltd, Jerusalem, Israel), anti-phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) antibody (Cell signalling Technology, Danvers, MA, USA), anti-NeuN antibody (MAB377, EMD Millipore Corporation, Billerica, MA, USA) and anti-sortilin antibody (Abcam, Cambridge, UK).

    Techniques: Western Blot, Immunoprecipitation, Fluorescence, Mapping Assay, Bimolecular Fluorescence Complementation Assay, Variant Assay, Enzyme-linked Immunosorbent Assay

    Construction of a novel peptide targeting proBDNF-sortilin Interaction. (A) Schematic diagram illustrating the design of a series of blocking peptides targeting proBDNF-sortilin interaction interface. Scr-bdnf84-83 (scr), scrambled peptide with permutation of peptide sequence at amino acid 84-93. (B) Immunoblots of co-immunoprecipitation (upper) or reverse co-immunoprecipitation (lower) of sortilin and proBDNF variants in cell lysates overexpressing full-length proBDNF and sortilin followed by peptide incubation obtained with antibodies against HA or Myc. IP, Immunoprecipitation; IB, Immunoblot. (C) Schematic diagram of the design of the Tat-tagged interfering peptide. Scr-bdnf89-98-Tat, Tat-tagged scrambled peptide with permutation of peptide sequence at amino acid 89-98. (D) Live fluorescence micrographs of 5FAM (green) or bright field in rat DRG neuronal cultures before (0 min) and incubated with 5 µM 5FAM-tagged bdnf89-98-Tat (bdnf-Tat) for 2 h. Scale bar represents 150 µm. (E) Fluorescence micrograph of 5FAM (green), sortilin (red) or DAPI (blue) in rat DRG neuronal cultures with peptides pre-treatment for 30 min. Scale bars represent 25 µm. (F) Left , fluorescence micrograph of BiFC assay (yellow) of HEK293T cells overexpressing full-length BDNF and sortilin with vehicle, 10 µM scr-Tat or bdnf-Tat pre-treatment for 30 min. Scale bars represent 25 µm. Right , Determination of the corrected total cell fluorescence (CTCF) of the BiFC signal. P <0.0001 , one-way ANOVA. *** P <0.0001, scr-Tat treatment versus bdnf-Tat treatment. Mean values ± SEM. n = 100 individual cells from 5 images. (G) Effect of 30 min peptide pre-treatment on activity-dependent secretion of BDNF in rat DRG neuronal cultures with high-potassium stimulus using ELISA. P <0.05, one-way ANOVA. * P <0.05, vehicle versus scr-Tat treatment or scr-Tat treatment versus bdnf-Tat treatment. Values are means ± SEM. Each data point represents the average of 3 independent experiments.

    Journal: Theranostics

    Article Title: A Novel Peptide Interfering with proBDNF-Sortilin Interaction Alleviates Chronic Inflammatory Pain

    doi: 10.7150/thno.29703

    Figure Lengend Snippet: Construction of a novel peptide targeting proBDNF-sortilin Interaction. (A) Schematic diagram illustrating the design of a series of blocking peptides targeting proBDNF-sortilin interaction interface. Scr-bdnf84-83 (scr), scrambled peptide with permutation of peptide sequence at amino acid 84-93. (B) Immunoblots of co-immunoprecipitation (upper) or reverse co-immunoprecipitation (lower) of sortilin and proBDNF variants in cell lysates overexpressing full-length proBDNF and sortilin followed by peptide incubation obtained with antibodies against HA or Myc. IP, Immunoprecipitation; IB, Immunoblot. (C) Schematic diagram of the design of the Tat-tagged interfering peptide. Scr-bdnf89-98-Tat, Tat-tagged scrambled peptide with permutation of peptide sequence at amino acid 89-98. (D) Live fluorescence micrographs of 5FAM (green) or bright field in rat DRG neuronal cultures before (0 min) and incubated with 5 µM 5FAM-tagged bdnf89-98-Tat (bdnf-Tat) for 2 h. Scale bar represents 150 µm. (E) Fluorescence micrograph of 5FAM (green), sortilin (red) or DAPI (blue) in rat DRG neuronal cultures with peptides pre-treatment for 30 min. Scale bars represent 25 µm. (F) Left , fluorescence micrograph of BiFC assay (yellow) of HEK293T cells overexpressing full-length BDNF and sortilin with vehicle, 10 µM scr-Tat or bdnf-Tat pre-treatment for 30 min. Scale bars represent 25 µm. Right , Determination of the corrected total cell fluorescence (CTCF) of the BiFC signal. P <0.0001 , one-way ANOVA. *** P <0.0001, scr-Tat treatment versus bdnf-Tat treatment. Mean values ± SEM. n = 100 individual cells from 5 images. (G) Effect of 30 min peptide pre-treatment on activity-dependent secretion of BDNF in rat DRG neuronal cultures with high-potassium stimulus using ELISA. P <0.05, one-way ANOVA. * P <0.05, vehicle versus scr-Tat treatment or scr-Tat treatment versus bdnf-Tat treatment. Values are means ± SEM. Each data point represents the average of 3 independent experiments.

    Article Snippet: The primary antibodies used included anti-proBDNF antibody (#ANT-006-AG, Alomone Labs Ltd, Jerusalem, Israel), anti-phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) antibody (Cell signalling Technology, Danvers, MA, USA), anti-NeuN antibody (MAB377, EMD Millipore Corporation, Billerica, MA, USA) and anti-sortilin antibody (Abcam, Cambridge, UK).

    Techniques: Blocking Assay, Sequencing, Western Blot, Immunoprecipitation, Incubation, Fluorescence, Bimolecular Fluorescence Complementation Assay, Activity Assay, Enzyme-linked Immunosorbent Assay

    α-BDNF, α-Myc, and α–pro-BDNF antibodies all generate similar staining patterns. (A) A schematic representation of the BDNF precursor pro-BDNF and the two cleavage products pro-peptide and BDNF. (B) Low-power view of a WT hippocampal section stained with anti-BDNF antibodies. Note the intense staining in the hilus of the DG and in SL of CA3, each of which contains the axon terminals of mossy fibers. (C and D) Higher magnification view of the DG (C) and CA3 region (D) of the cbdnf ko hippocampus stained with anti-BDNF. Note the absence of immunoreactive signals in all cellular and neuropil layers. GCL, granule cell layer; H, hilus; IML, inner molecular layer; PCL, pyramidal cell layer. (E) Bdnf-Myc hippocampi stained with Myc antibodies show a similar staining pattern to that produced by BDNF antibodies. (F and G) Note the absence of staining in the corresponding DG (F) and CA3 regions (G) of WT sections treated with Myc antibodies. (H) Polyclonal pro-BDNF antibodies yield a similar pattern to that of anti-BDNF. (I and J) The same antibodies do not produce an immunoreactive signal in hippocampal sections from cbdnf ko animals. (B, E, and H) Arrows denote the end bulb of the mossy fiber projection, which delineates CA3 and CA1. Note the relative lack of staining in CA1 in WT and Bdnf-Myc sections. Bars: (B, E, and H) 500 µm; (C, F, and I) 100 µm; (D, G, and J) 50 µm.

    Journal: The Journal of Cell Biology

    Article Title: BDNF and its pro-peptide are stored in presynaptic dense core vesicles in brain neurons

    doi: 10.1083/jcb.201201038

    Figure Lengend Snippet: α-BDNF, α-Myc, and α–pro-BDNF antibodies all generate similar staining patterns. (A) A schematic representation of the BDNF precursor pro-BDNF and the two cleavage products pro-peptide and BDNF. (B) Low-power view of a WT hippocampal section stained with anti-BDNF antibodies. Note the intense staining in the hilus of the DG and in SL of CA3, each of which contains the axon terminals of mossy fibers. (C and D) Higher magnification view of the DG (C) and CA3 region (D) of the cbdnf ko hippocampus stained with anti-BDNF. Note the absence of immunoreactive signals in all cellular and neuropil layers. GCL, granule cell layer; H, hilus; IML, inner molecular layer; PCL, pyramidal cell layer. (E) Bdnf-Myc hippocampi stained with Myc antibodies show a similar staining pattern to that produced by BDNF antibodies. (F and G) Note the absence of staining in the corresponding DG (F) and CA3 regions (G) of WT sections treated with Myc antibodies. (H) Polyclonal pro-BDNF antibodies yield a similar pattern to that of anti-BDNF. (I and J) The same antibodies do not produce an immunoreactive signal in hippocampal sections from cbdnf ko animals. (B, E, and H) Arrows denote the end bulb of the mossy fiber projection, which delineates CA3 and CA1. Note the relative lack of staining in CA1 in WT and Bdnf-Myc sections. Bars: (B, E, and H) 500 µm; (C, F, and I) 100 µm; (D, G, and J) 50 µm.

    Article Snippet: Pro-BDNF was detected with a rabbit polyclonal antibody (anti–pro-BDNF; #ANT-006, batch AN-03; Alomone Labs) raised against the prodomain of BDNF protein (see ).

    Techniques: Staining, Produced